Binds Hormone, Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Neurotransmitter (e.g., Insulin, Human Chorionic Gonadotropin, Glucagon, Cardiodilatin, Interleukin, Interferon, Norepinephrine, Epinephrine, Acetylcholine, Etc.) Patents (Class 530/389.2)
  • Patent number: 10894833
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: January 19, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren
  • Patent number: 9393304
    Abstract: The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: July 19, 2016
    Assignee: Ablynx N.V.
    Inventors: Jason E. Fernandez, Daniel A. Dixon, Andrea Paulson
  • Publication number: 20150140580
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Application
    Filed: February 29, 2012
    Publication date: May 21, 2015
    Applicant: Gilead Biologics, Inc.
    Inventors: Victoria Smith, Scott McCauley
  • Publication number: 20150139983
    Abstract: The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the pharmaceutical compositions of the invention.
    Type: Application
    Filed: June 12, 2013
    Publication date: May 21, 2015
    Inventors: Arnon Karni, Yifat Amir Levi, Nataly Urshanski, Karin Bernadet Fainberg
  • Publication number: 20150140011
    Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).
    Type: Application
    Filed: May 23, 2013
    Publication date: May 21, 2015
    Applicant: ARGEN-X B.V.
    Inventors: Christophe Blanchetot, Johannes De Haard, Torsten Dreier, Natalie De Jonge, Paul Sebastian Van Der Woning, Nicolas Ongenae
  • Publication number: 20150132319
    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
    Type: Application
    Filed: March 6, 2013
    Publication date: May 14, 2015
    Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
  • Publication number: 20150132320
    Abstract: The present invention is directed to modified antibodies, including anti-TNF? antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.
    Type: Application
    Filed: December 15, 2014
    Publication date: May 14, 2015
    Inventors: Chris M. Chumsae, Zehra Kaymakcalan
  • Patent number: 9029510
    Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.
    Type: Grant
    Filed: March 30, 2013
    Date of Patent: May 12, 2015
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
  • Publication number: 20150118226
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
    Type: Application
    Filed: December 31, 2014
    Publication date: April 30, 2015
    Inventors: David J. King, Peter Bowers, Robert A. Horlick, Tamlyn Yee Neben
  • Publication number: 20150118156
    Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 30, 2015
    Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
  • Publication number: 20150118155
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Application
    Filed: June 14, 2012
    Publication date: April 30, 2015
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Xiangming Gao
  • Patent number: 9017674
    Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: April 28, 2015
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey Yarranton
  • Patent number: 9017686
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Jenny M. Bostrom, Germaine Fuh
  • Publication number: 20150110805
    Abstract: Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases. In addition, the present invention relates to the determination that regulator cells are cycling in degenerative diseases. Based on these realizations, the present invention provides methods for treating conditions such as autoimmune diseases, degenerative diseases, and graft-versus-host disease. The present invention also relates to methods of determining when therapy should be administered to a patient.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Martin Leonard Ashdown, Luisa Maria Ashdown
  • Publication number: 20150110787
    Abstract: A polypeptide, antagonist, and antibody that specifically bind to and inhibit VEGF-C and uses thereof in a method of inhibiting angiogenesis and a method of preventing, treating, and/or diagnosing a disease associated with activation and/or overexpression of VEGF-C, using the antibody, and a method of detecting the presence of VEGF-C in a sample.
    Type: Application
    Filed: October 20, 2014
    Publication date: April 23, 2015
    Inventors: Seok Kyun KIM, Sang Yeul HAN, Kwang Hoon LEE, Kyung Eun KIM
  • Publication number: 20150110803
    Abstract: The present invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods for producing such low AR compositions using displacement chromatography. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: November 13, 2013
    Publication date: April 23, 2015
    Inventors: Chen Wang, Germano Coppola, Chris Chumsae
  • Patent number: 9005625
    Abstract: The present invention provides conjugates formed between toxins and sugars and toxins and peptides, such as antibodies. In an exemplary embodiment, a toxin-sugar construct is conjugated to an antibody through an intact glycosyl linking group.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: April 14, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Zhi-Guang Wang
  • Publication number: 20150098938
    Abstract: Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCAT1) expression, function or activity are provided. In particular, inhibitors of ALCAT1 are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCAT1 modulators are provided.
    Type: Application
    Filed: February 15, 2013
    Publication date: April 9, 2015
    Applicant: The Penn State Research Foundation
    Inventor: Yuguang Shi
  • Publication number: 20150098949
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 3, 2014
    Publication date: April 9, 2015
    Inventors: AUSTIN L. GURNEY, AARON KEN SATO, CHRISTOPHER JOHN BOND
  • Patent number: 9000134
    Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: April 7, 2015
    Inventors: Wallace B. Haigh, Donald L. Very, Jr.
  • Patent number: 8992916
    Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: March 31, 2015
    Assignee: Novartis AG
    Inventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
  • Patent number: 8992920
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 8992908
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventors: Jeffrey T.L. Smith, Leon F. Garcia-Martinez, Andrew L. Feldhaus
  • Publication number: 20150086568
    Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
    Type: Application
    Filed: November 20, 2014
    Publication date: March 26, 2015
    Applicant: GENENTECH, INC.
    Inventors: Germaine FUH, Chingwei V. LEE
  • Publication number: 20150086552
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Application
    Filed: May 21, 2013
    Publication date: March 26, 2015
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty, Milan Gao, Steven Sheriff, Noah Ditto, Nels B. Hamacher
  • Publication number: 20150064201
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanising antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 5, 2015
    Inventors: GARY PETER BEMBRIDGE, CHUN-WA CHUNG, SUSANNAH KAREN FORD, IAN KIRBY, RUTH MCADAM, MARIA FEENEY
  • Publication number: 20150050291
    Abstract: A method for detecting and/or monitoring a chronic inflammation condition associated with rheumatoid arthritis. The method comprises the steps of: (i) collecting a sample; (ii) detecting in the sample, one or more of a HMGN1 protein, a LCP-1 protein, a prtn3 protein, a sec22b protein, and a PYGL glycogen phosphorylase protein thereby producing a result; and (iii) correlating the result with a control. A test kit for diagnosing or monitoring a chronic inflammatory condition associated with rheumatoid arthritis. The test kit comprises an antibody for complexing with one of a HMGN1 protein, a LCP-1 protein, a prtn3 protein, a sec22b protein, and a PYGL glycogen phosphorylase protein.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 19, 2015
    Applicant: UNIVERSITYOF MANITOBA
    Inventor: Neelhoffer Mookerjee
  • Publication number: 20150050287
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Application
    Filed: September 1, 2011
    Publication date: February 19, 2015
    Applicant: VACCINEX, INC.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • Publication number: 20150044178
    Abstract: The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) ? signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.
    Type: Application
    Filed: December 27, 2012
    Publication date: February 12, 2015
    Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SENJU PHARMACEUTICAL CO., LTD., THE DOSHISHA
    Inventors: Shigeru Kinoshita, Noriko Koizumi, Naoki Okumura
  • Publication number: 20150045542
    Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
    Type: Application
    Filed: October 23, 2014
    Publication date: February 12, 2015
    Inventor: CHRIS M. CHUMSAE
  • Publication number: 20150037349
    Abstract: The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against Tumor Necrosis Factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-Tumor Necrosis Factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis. Compositions and methods for enhancing therapeutic potential of anti-Tumor Necrosis Factor-alpha polypeptides are provided, including linking the polypeptide to an albumin-binding domain and/or de-immunizing the polypeptide, to provide therapeutic agents with good solubility, enhanced serum half-life, and/or reduced immunogenicity, while substantially maintaining the specific binding properties of the anti-Tumor Necrosis Factor-alpha polypeptides.
    Type: Application
    Filed: September 19, 2012
    Publication date: February 5, 2015
    Inventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Rui Pedro da Silva Albuquerque e Freitas, Sara Ferreira Llorente Grancho Lourenço
  • Publication number: 20150037813
    Abstract: The present invention provides a means and a method for specifically measuring a substance such as a small substance with high sensitivity by a sandwich method. Specifically, the present invention provides an antibody capable of specifically binding to an affinity complex and a method of measuring of the affinity complex comprising measuring the affinity complex using the antibody capable of specifically binding to the affinity complex. The antibody of the present invention may be a full-length antibody. The antibody of the present invention may also have a region derived from an immunoglobulin from an animal having an ability of gene conversion (e.g., a complementarity-determining region, a framework region, or a variable region). Examples of at least one factor that constitutes the affinity complex include a small substance or a protein (e.g., antibody).
    Type: Application
    Filed: July 4, 2012
    Publication date: February 5, 2015
    Applicant: FUJIREBIO INC.
    Inventor: Yoshie GOISHI
  • Publication number: 20150037248
    Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
    Type: Application
    Filed: February 13, 2013
    Publication date: February 5, 2015
    Applicant: Agency for Science, Technology and Research
    Inventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar, Florent Ginhoux, Pingyu Zhong
  • Publication number: 20150037351
    Abstract: The present invention relates to an inhibitor of the P2Y2 receptor or an inhibitor of the P2Y2 receptor signaling pathway for use in preventing the metastasis of tumours or as a lead compound for developing a drug for preventing the metastasis of tumours.
    Type: Application
    Filed: March 21, 2013
    Publication date: February 5, 2015
    Inventors: Stefan Offermanns, Boris Strilic, Dagmar Schumacher, Nina Wettschureck
  • Publication number: 20150030609
    Abstract: The subject invention identifies CC chemokine ligand 20 (CCL20) as a novel biomarker for diagnosis of traumatic brain injury and/or neurodegeneration in the brain. The subject invention also provides treatment methods for traumatic brain injury and/or neurodegeneration in the brain by modulating systemic and/or brain-specific CCL20-CCR6 signaling. Also provided are uses of CCL20-CCR6 signaling a target for screening for therapeutic agents that are useful for treatment of traumatic brain injury.
    Type: Application
    Filed: May 3, 2012
    Publication date: January 29, 2015
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Subhra Mohapatra, Shyam S. Mohapatra, Keith Ronald Pennypacker, Mahasweta Das, Christopher Charles Leonardo
  • Publication number: 20150030605
    Abstract: The invention encompasses polypeptides, polynucleotides, and antibodies, for Artemin and related ligands, including Persephin (PSPN). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further encompasses diagnostics and therapeutics, especially for cancer, and particularly breast cancer, colon cancer, prostate cancer, endometrial cancer, lung cancer, stomach cancer, liver cancer, and others, comprising one or more of the disclosed polypeptides, polynucleotides, antibodies, expression vectors, host cells, or compositions thereof. Particularly encompasses are inhibitors of Artemin and/or related ligands, and uses for these inhibitors.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 29, 2015
    Inventors: Liu Dongxu, Peter Edward Lobie
  • Patent number: 8940875
    Abstract: The invention includes a process for extracting a target protein from Escherichia coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: January 27, 2015
    Assignee: Genentech, Inc.
    Inventor: Richard L. Gehant
  • Publication number: 20150017738
    Abstract: Method for obtaining an antibody or antibody fragment to a conformational epitope specific for oxidized, inactive human parathyroid hormone and fragments thereof; a method for removal of oxidized, inactive human parathyroid hormone from a sample of body fluid; methods of determining the concentration of active parathyroid hormone in a sample, and an in vitro method of diagnosis of renal failure or secondary hyperthyroidism in patients on dialysis.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 15, 2015
    Applicant: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher, Hans Juergen Groen, Heinz Juergen Roth
  • Publication number: 20150017699
    Abstract: The present invention is generally directed to internally functionalized graphene substrates, methods of making such substrates and methods of using such substrates. In one aspect, the present invention is a graphene substrate. The substrate comprises edge and non-edge regions. Organic or inorganic molecules are bound to the non-edge regions of the substrate, and the organic or inorganic molecules are present on the substrate edges at a population greater than about one molecule per 10,000 nm2.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 15, 2015
    Applicant: NANOTECH BIOMACHINES, INC.
    Inventors: Jeffrey Alan McKinney, William Emerson Martinez
  • Patent number: 8932592
    Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: January 13, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
  • Publication number: 20150004162
    Abstract: Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to DR4 and/or DR5 and aspects relating to such constructs and their use.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 1, 2015
    Inventors: Arun K. Kashyap, Ramesh R. Bhatt, Michael Horowitz, Lawrence Horowitz, Sihong Zhou, Ryann E. O'Neil, Charles H. Hannum, Aaron L. Kurtzman, Li Xu
  • Publication number: 20140363445
    Abstract: The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.
    Type: Application
    Filed: August 11, 2014
    Publication date: December 11, 2014
    Applicant: ZENYTH OPERATIONS PTY LTD
    Inventors: Andrew Nash, Felicity Meredith Dunlop, Manuel Baca, Louis Jerry Fabri, Pierre David Scotney
  • Publication number: 20140363444
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: June 12, 2014
    Publication date: December 11, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Rachel Rebecca BARRETT, Keith CANADA, Katrina Mary CATRON, Robert COPENHAVER, Lee Edward Frego, Ernest Lee Raymond, Sanjaya SINGH, Xiangyang ZHU
  • Publication number: 20140356363
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Application
    Filed: May 31, 2014
    Publication date: December 4, 2014
    Applicant: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Publication number: 20140356356
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Application
    Filed: September 27, 2012
    Publication date: December 4, 2014
    Applicant: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Publication number: 20140356357
    Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes human TNF?. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 4, 2014
    Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
  • Publication number: 20140348846
    Abstract: Provided herein are compositions comprising anti-HLA-Ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies strongly mimic IVIg in immunomodulatory or immunosuppressive activities. Methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.
    Type: Application
    Filed: January 10, 2013
    Publication date: November 27, 2014
    Inventors: Mepur H. Ravindranath, Paul I. Terasaki
  • Publication number: 20140349877
    Abstract: Methods and compositions for detecting and diagnosing Parkinson's disease are disclosed.
    Type: Application
    Filed: December 7, 2012
    Publication date: November 27, 2014
    Inventors: Howard E. Gendelman, R. Lee Mosley, Jessica A. Saunders
  • Publication number: 20140348843
    Abstract: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
    Type: Application
    Filed: May 28, 2014
    Publication date: November 27, 2014
    Applicant: NEOTOPE BIOSCIENCES LIMITED
    Inventors: Dale B. Schenk, Tarlochan S. Nijjar, Philip W. Payne, Robin Barbour
  • Patent number: 8895705
    Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: November 25, 2014
    Assignee: Bionovion Holding B.V.
    Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan